A Prospective Study on the Progression, Recurrence, and Regression of Cervical Lesions: Assessing Various Screening Approaches

• Published in: Journal of clinical medicine Vol. 13; no. 5; p. 1368
• Main Authors: Gisca, Tudor, Munteanu, Iulian-Valentin, Vasilache, Ingrid-Andrada, Melinte-Popescu, Alina-Sinziana, Volovat, Simona, Scripcariu, Ioana-Sadyie, Balan, Raluca-Anca, Pavaleanu, Ioana, Socolov, Razvan, Carauleanu, Alexandru, Vaduva, Constantin, Melinte-Popescu, Marian, Adam, Ana-Maria, Adam, Gigi, Vicoveanu, Petronela, Socolov, Demetra
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 28.02.2024; MDPI
• Subjects: Analysis; Biopsy; Cancer; Causes of; Cellular biology; Cervical cancer; Complications and side effects; Development and progression; Diagnosis; Diseases; Health aspects; Histology; Human papillomavirus; Infections; Laboratories; Medical research; Medicine, Experimental; Pap smear; Papillomavirus infections; Relapse; Stains & staining; Women; Romania; United States > US; Germany; p16/Ki67 dual staining; cervical lesions; clinical risk factors; cervical cytology; HPV genotyping
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm13051368

(1) Background: The prediction of cervical lesion evolution is a challenge for clinicians. This prospective study aimed to determine and compare the predictive accuracy of cytology, HPV genotyping, and p16/Ki67 dual staining alone or in combination with personal risk factors in the prediction of progression, regression, or persistence of cervical lesions in human papillomavirus (HPV)-infected patients; (2) Methods: This prospective study included HPV-positive patients with or without cervical lesions who underwent follow-up in a private clinic. We calculated the predictive performance of individual tests (cervical cytology, HPV genotyping, CINtecPlus results, and clinical risk factors) or their combination in the prediction of cervical lesion progression, regression, and persistence; (3) Results: The highest predictive performance for the progression of cervical lesions was achieved by a model comprising a Pap smear suggestive of high-grade squamous intraepithelial lesion (HSIL), the presence of 16/18 HPV strains, a positive p16/Ki67 dual staining result along with the presence of at least three clinical risk factors, which had a sensitivity (Se) of 74.42%, a specificity of 97.92%, an area under the receiver operating curve (AUC) of 0.961, and an accuracy of 90.65%. The prediction of cervical lesion regression or persistence was modest when using individual or combined tests; (4) Conclusions: Multiple testing or new biomarkers should be used to improve HPV-positive patient surveillance, especially for cervical lesion regression or persistence prediction.